The interactions of anticancer agents with tea catechins: Current evidence from preclinical studies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 10, 2014, Pages 1343-1350

  Shang, Weihu ^a   Lu, Weidong ^b   Han, Mei ^a   Qiao, Jinping ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Drug interactions; EGCG; Pharmacodynamics; Pharmacokinetics; Tea catechins

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CATECHIN; CELECOXIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; ERLOTINIB; FLUOROURACIL; IRINOTECAN; PACLITAXEL; SUNITINIB; TAMOXIFEN; TEA;

ARTICLE; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; NONHUMAN; PHARMACODYNAMICS; PRECLINICAL STUDY; TEA; TUMOR VOLUME; XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; FOOD DRUG INTERACTION; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHIN; DRUG SYNERGISM; FOOD-DRUG INTERACTIONS; HUMANS; NEOPLASMS; TEA;

EID: 84935450835     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140829123651     Document Type: Article

References (69)

1. Yang, C.S.; Pan, E. The effects of green tea polyphenols on drug metabolism. Exp. Opin. Drug Metab. Toxicol., 2012, 8(6), 677-689.
2. Sang, S.; Lambert, J.D.; Ho, C.T.; Yang, C.S. The chemistry and biotransformation of tea constituents. Pharmacol. Res., 2011, 64(2), 87-99.
3. Bushman, J.L. Green tea and cancer in humans: A review of the literature. Nutr. Cancer, 1998, 31(3), 151-159.
4. Frei, B.; Higdon, J.V. Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. J. Nutr., 2003, 133(10), 3275S-3284S.
5. Song, J.M.; Lee, K.H.; Seong, B.L. Antiviral effect of catechins in green tea on influenza virus. Antivir. Res., 2005, 68(2), 66-74.
6. Gradisar, H.; Pristovsek, P.; Plaper, A.; Jerala, R. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J. Med. Chem., 2007, 50(2), 264-271.
7. Yang, C.S.; Wang, X.; Lu, G.; Picinich, S.C. Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer, 2009, 9(6), 429-439.
8. Beltz, L.A.; Bayer, D.K.; Moss, A.L.; Simet, I.M. Mechanisms of cancer prevention by green and black tea polyphenols. Anti-Cancer Agents Med. Chem., 2006, 6(5), 389-406.
9. Lin, J.K.; Lin-Shiau, S.Y. Mechanisms of hypolipidemic and antiobesity effects of tea and tea polyphenols. Mol. Nutr. Food Res., 2006, 50(2), 211-217.
10. Ghiringhelli, F.; Rebe, C.; Hichami, A.; Delmas, D. Immunomodulation and Anti-inflammatory roles of polyphenols as anticancer agents. Anti-Cancer Agents Med. Chem., 2012, 12(8), 852-873.
11. Hodgson, J.M.; Puddey, I.B.; Burke, V.; Beilin, L.J.; Jordan, N. Effects on blood pressure of drinking green and black tea. J. Hypertens., 1999, 17(4), 457-463.
12. Chow, H.H.S.; Hakim, I.A. Pharmacokinetic and chemoprevention studies on tea in humans. Pharmacol. Res., 2011, 64(2), 105-112.
13. Yang, C.S.; Wang, H.; Li, G.X.; Yang, Z.; Guan, F.; Jin, H. Cancer prevention by tea: Evidence from laboratory studies. Pharmacol. Res., 2011, 64(2), 113-122.
14. Yuan, J.M.; Sun, C.; Butler, L.M. Tea and cancer prevention: Epidemiological studies. Pharmacol. Res., 2011, 64(2), 123-135.
15. Lambert, J.D.; Yang, C.S. Mechanisms of cancer prevention by tea constituents. J. Nutr., 2003, 133(10), 3262S-3267S.
16. Yang, C.S.; Li, G.; Yang, Z.; Guan, F.; Chen, A.; Ju, J. Cancer prevention by tocopherols and tea polyphenols. Cancer Lett., 2013, 334(1), 79-85.
17. Yang, C.S.; Wang, Z.Y. Tea and cancer. J. Natl. Cancer I, 1993, 85(13), 1038-1049.
18. Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem. Pharmacol., 2011, 82(12), 1807-1821.
19. Moyers, S.B.; Kumar, N.B. Green tea polyphenols and cancer chemoprevention: Multiple mechanisms and endpoints for phase II trials. Nutr. Rev., 2004, 62(5), 204-211.
20. Suganuma, M.; Saha, A.; Fujiki, H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci., 2011, 102(2), 317-323.
21. Fujiki, H.; Suganuma, M.; Imai, K.; Nakachi, K. Green tea: Cancer preventive beverage and/or drug. Cancer Lett., 2002, 188(1-2), 9-13.
22. Fujiki, H.; Suganuma, M. Green tea: An effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett., 2012, 324(2), 119-125.
23. Lecumberri, E.; Dupertuis, Y.M.; Miralbell, R.; Pichard, C. Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin. Nutr., 2013, 32(6), 894-903.
24. Mohan, A.; Narayanan, S.; Sethuraman, S.; Krishnan, U.M. Combination of plant polyphenols & anti-cancer molecules: A novel treatment strategy for cancer chemotherapy. Anti-Cancer Agents Med. Chem., 2013, 13(2), 281-295.
25. Khan, N.; Mukhtar, H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett., 2008, 269(2), 269-280.
26. Dumontet, C.; Jordan, M.A. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat. Rev. Drug Discovery, 2010, 9(11), 587-587.
27. Luo, T.; Wang, J.; Yin, Y.; Hua, H.; Jing, J.; Sun, X.; Li, M.; Zhang, Y.; Jiang, Y. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res., 2010, 12(1), R8.
28. Ermakova, S.P.; Kang, B.S.; Choi, B.Y.; Choi, H.S.; Schuster, T.F.; Ma, W.-Y.; Bode, A.M.; Dong, Z. (-)-epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res., 2006, 66(18), 9260-9269.
29. Wang, J.; Yin, Y.; Hua, H.; Li, M.; Luo, T.; Xu, L.; Wang, R.; Liu, D.; Zhang, Y.; Jiang, Y. Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response. J. Cell. Mol. Med., 2009, 13(9B), 3888-3897.
30. Stearns, M.E.; Wang, M. Synergistic Effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Trans. Oncology, 2011, 4(3), 147-156.
31. Schmidt, M.; Bastians, H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Update., 2007, 10(4-5), 162-181.
32. Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents, 2002, 2(1), 1-17.
33. Wu, H.J.; Xin, Y.; Xiao, Y.P.; Zhao, J. Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Cancer Biother. Radio., 2012, 27(3), 204-209.
34. Chinnaiyan, P.; Huang, S.M.; Vallabhaneni, G.; Armstrong, E.; Varambally, S.; Tomlins, S.A.; Chinnaiyan, A.M.; Harari, P.M. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by Erlotinib (Tarceva). Cancer Res., 2005, 65(8), 3328-3335.
35. Zhang, X.; Zhang, H.; Tighiouart, M.; Lee, J.E.; Shin, H.J.; Khuri, F.R.; Yang, C.S.; Chen, Z.; Shin, D.M. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3- gallate and EGFR tyrosine kinase inhibitor. Int. J. Cancer, 2008, 123(5), 1005-1014.
36. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2005, 2(3), 225-235.
37. Milligan, S.A.; Burke, P.; Coleman, D.T.; Bigelow, R.L.; Steffan, J.J.; Carrol, J.L.; Williams, B.J.; Cardelli, J.A. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin. Cancer Res., 2009, 15(15), 4885-4894.
38. Howe, L.R.; Subbaramaiah, K.; Patel, J.; Masferrer, J.L.; Deora, A.; Hudis, C.; Thaler, H.T.; Muller, W.J.; Du, B.H.; Brown, A.M.C.; Dannenberg, A.J. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res., 2002, 62(19), 5405-5407.
39. Huang, K.H.; Kuo, K.L.; Chen, S.C.; Weng, T.I.; Chuang, Y.T.; Tsai, Y.C.; Pu, Y.S.; Chiang, C.K.; Liu, S.H. Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PLoS One, 2012, 7(3), e33615.
40. Adhami, V.M.; Malik, A.; Zaman, N.; Sarfaraz, S.; Siddiqui, I.A.; Syed, D.N.; Afaq, F.; Pasha, F.S.; Saleem, M.; Mukhtar, H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res., 2007, 13(5), 1611-1619.
41. Hardtner, C.; Multhoff, G.; Falk, W.; Radons, J. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur. J. Pharmacol., 2012, 684(1-3), 36-43.
42. Wassermann, K.; Markovits, J.; Jaxel, C.; Capranico, G.; Kohn, K.W.; Pommier, Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol., 1990, 38(1), 38-45.
43. Liang, G.; Tang, A.; Lin, X.; Li, L.; Zhang, S.; Huang, Z.; Tang, H.; Li, Q.Q. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int. J. Oncol., 2010, 37(1), 111-123.
44. Stearns, M.E.; Amatangelo, M.D.; Varma, D.; Sell, C.; Goodyear, S.M. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: Inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am. J. Pathol., 2010, 177(6), 3169-3179.
45. Hardenbergh, P.H.; Munley, M.T.; Bentel, G.C.; Kedem, R.; Borges-Neto, S.; Hollis, D.; Prosnitz, L.R.; Marks, L.B. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results. Int. J. Radiat. Oncol. Biol. Phys., 2001, 49(4), 1023-1028.
46. Kozluca, O.; Olcay, E.; Surucu, S.; Guran, Z.; Kulaksiz, T.; Uskent, N. Prevention of doxorubicin induced cardiotoxicity by catechin. Cancer Lett., 1996, 99(1), 1-6.
47. Li, W.; Nie, S.; Xie, M.; Chen, Y.; Li, C.; Zhang, H. A major green tea component, (-)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. J. Agric. Food. Chem., 2010, 58(16), 8977-8982.
48. Boulikas, T.; Vougiouka, M. Cisplatin and platinum drugs at the molecular level (review). Oncol. Rep., 2003, 10(6), 1663-1682.
49. Lee, S.H.; Nam, H.J.; Kang, H.J.; Kwon, H.W.; Lim, Y.C. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur. J. Cancer, 2013, 49(15), 3210-3218.
50. Tang, S.N.; Fu, J.; Shankar, S.; Srivastava, R.K. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One, 2012, 7(2), e31067.
51. Kwak, T.W.; Kim Do, H.; Chung, C.W.; Lee, H.M.; Kim, C.H.; Jeong, Y.I.; Kang, D.H. Synergistic anticancer effects of Vorinostat and epigallocatechin-3-gallate against HuCC-T1 human cholangiocarcinoma cells. Evid. Based Complement. Alternat. Med., 2013, 185158.
52. Nihal, M.; Roelke, C.T.; Wood, G.S. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)- epigallocatechin-3-gallate (EGCG). Pharm. Res., 2010, 27(6), 1103-1114.
53. Mohan, N.; Karmakar, S.; Banik, N.L.; Ray, S.K. SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. Neurochem. Res., 2011, 36(8), 1383-1396.
54. Farabegoli, F.; Papi, A.; Orlandi, M. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci. Rep., 2011, 31(2), 99-108.
55. Davenport, A.; Frezza, M.; Shen, M.; Ge, Y.; Huo, C.; Chan, T.H.; Dou, Q.P. Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. Int. J. Mol. Med., 2010, 25(3), 465-470.
56. Lee, T.C.; Cheng, I.C.; Shue, J.J.; Wang, T.C. Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells. Toxicol. Appl. Pharmacol., 2011, 250(1), 69-77.
57. Bushra, R.; Aslam, N.; Khan, A.Y. Food-drug interactions. Oman Med. J., 2011, 26(2), 77-83.
58. Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer, 2003, 3(5), 330-338.
59. Qiao, J.P.; Gu, C.X.; Shang, W.H.; Du, J.L.; Yin, W.; Zhu, M.L.; Wang, W.; Han, M.; Lu, W.D. Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food Chem. Toxicol., 2011, 49(6), 1410-1415.
60. Smith, N.F.; Figg, W.D.; Sparreboom, A. Pharmacogenetics of irinotecan metabolism and transport: An update. Toxicol. in vitro, 2006, 20(2), 163-175.
61. Lin, L.C.; Wang, M.N.; Tsai, T.H. Food-drug interaction of (-)- epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem. Biol. Interact., 2008, 174(3), 177-182.
62. Mouridsen, H.; Giobbie-Hurder, A.; Goldhirsch, A.; Thurlimann, B.; Paridaens, R.; Smith, I.; Mauriac, L.; Forbes, J.; Price, K.N.; Regan, M.M.; Gelber, R.D.; Coates, A.S. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med., 2009, 361(8), 766-776.
63. Shin, S.C.; Choi, J.S. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anti-Cancer Drug., 2009, 20(7), 584-588.
64. Richardson, P.G.; Sonneveld, P.; Schuster, M.W.; Irwin, D.; Stadtmauer, E.A.; Facon, T.; Harousseau, J.L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San-Miguel, J.F.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W.S.; Boral, A.L.; Esseltine, D.L.; Porter, J.B.; Schenkein, D.; Anderson, K.C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med., 2005, 352(24), 2487-2498.
65. Ludwig, H.; Khayat, D.; Giaccone, G.; Facon, T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer, 2005, 104(9), 1794-1807.
66. Golden, E.B.; Lam, P.Y.; Kardosh, A.; Gaffney, K.J.; Cadenas, E.; Louie, S.G.; Petasis, N.A.; Chen, T.C.; Schonthal, A.H. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood, 2009, 113(23), 5927-5937.
67. Demetri, G.D.; Van Oosterom, A.T.; Garrett, C.R.; Blackstein, M.E.; Shah, M.H.; Verweij, J.; McArthur, G.; Judson, I.R.; Heinrich, M.C.; Morgan, J.A.; Desai, J.; Fletcher, C.D.; George, S.; Bello, C.L.; Huang, X.; Baum, C.M.; Casali, P.G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet, 2006, 368(9544), 1329-1338.
68. Ge, J.; Tan, B.X.; Chen, Y.; Yang, L.; Peng, X.C.; Li, H.Z.; Lin, H.J.; Zhao, Y.; Wei, M.; Cheng, K.; Li, L.H.; Dong, H.; Gao, F.; He, J.P.; Wu, Y.; Qiu, M.; Zhao, Y.L.; Su, J.M.; Hou, J.M.; Liu, J.Y. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: Potential risk of diminished sunitinib bioavailability. J. Mol. Med., 2011, 89(6), 595-602.
69. Shen, M.; Chan, T.H.; Dou, Q.P. Targeting tumor ubiquitinproteasome pathway with polyphenols for chemosensitization. Anti-Cancer Agents Med. Chem., 2012, 12(8), 891-901.